Q1--Does Wallstreet reward young biotech and drug companies based on revenues and net income, or based on potential for a successful drug?
Q2--When ZIOP went from $5.13 on Mar 25th to $1.82 on Mar 26th, was there any change in net income or revenue stream on the books during that 24 hr period, or was there any real rational behind the new value of the stock price, or is stock worth what someone is willing to pay for it?
Q3--does the 5 day chart on ZIOP look bullish now?
Q4--did Friday end with the chart aiming down, or did the last minute buying aim it up?
Q5--Is Wallstreet more afraid of the risks of owning ZIOP now(fear), or the risk of missing the profit train leaving the station(greed-buying the news to sell the fact)?
OBSERVATION---On March 25th the fear of owning ZIOP was huge, and no one wanted it at any price. Very few people bought it as it fell to $1.82 in a few short hours. As the price goes back up there are fewer people to sell because not very many people bought during the gap down. ZIOP is defying gravity at the moment. Monday should be another up day as people buy the news.